Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees
- PMID: 35873251
- PMCID: PMC9300865
- DOI: 10.3389/fpsyt.2022.883869
Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees
Abstract
Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. The main aim of the present study was investigation of the effects of psilocybin-containing truffles, when taken in a supportive group setting, on ratings of state and trait anxiety across self-reported healthy volunteers. Attendees of psilocybin ceremonies were asked to complete a test battery at three separate occasions: before the ceremony (baseline), the morning after, and 1 week after the ceremony. The test battery included questionnaires assessing state and trait anxiety (State-Trait Anxiety Inventory), mindfulness capacities (Five Facet Mindfulness Questionnaire), and personality (Big Five Inventory). Additionally, the psychedelic experience was quantified with the Persisting Effects Questionnaire and the Ego Dissolution Inventory. The total amount of psilocybin-containing truffles consumed by each participant was recorded, and a sample of the truffles was analyzed to determine psilocin concentrations. Fifty-two attendees (males = 25; females = 25; others = 2) completed parts of the baseline assessment, 46 (males = 21; females = 24; others = 1) completed assessments the morning after the ceremony, and 23 (males = 10; females = 13) completed assessments at the 1-week follow-up. Average psilocin consumption across individuals was 27.1 mg. The morning after the ceremony, we observed medium reductions in anxiety measures (both state and trait) compared to baseline ( = 6.4; p < 0.001 and = 6; p = 0.014, respectively), which persisted over a 1-week period post-ceremony ( = 6.7; p = 0.001 and = 8.6; p = 0.004, respectively). At 1 week post-ceremony, the non-judging facet of the mindfulness scale was increased ( = 1.5; p = 0.03), while the personality trait neuroticism decreased ( = 5.2; p = 0.005), when compared to baseline. Additionally, we found ratings of ego dissolution (mean: 59.7, SD: 28.3) and changes in neuroticism to be the strongest predictors of reductions in state and trait anxiety, respectively. In sum, results suggest rapid and persisting (up to 1 week) anxiolytic effects in individuals with sub-clinical anxiety symptoms, which are related to the acute experience of ego dissolution, as well as lasting changes in trait neuroticism. Results also add support to the feasibility and potential efficacy of group sessions with psychedelics. To understand whether these effects extend to wider populations suffering from heightened anxiety, and the mechanisms involved, further experimental research is needed.
Keywords: anxiety; mindfulness; neuroticism; personality; psilocybin.
Copyright © 2022 Kiraga, Kuypers, Uthaug, Ramaekers and Mason.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being.Front Pharmacol. 2021 Oct 1;12:721537. doi: 10.3389/fphar.2021.721537. eCollection 2021. Front Pharmacol. 2021. PMID: 34658861 Free PMC article.
-
Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study.Front Pharmacol. 2022 Oct 26;13:884703. doi: 10.3389/fphar.2022.884703. eCollection 2022. Front Pharmacol. 2022. PMID: 36386199 Free PMC article.
-
Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.Sci Rep. 2019 Oct 24;9(1):14914. doi: 10.1038/s41598-019-50612-3. Sci Rep. 2019. PMID: 31649304 Free PMC article. Clinical Trial.
-
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520. Molecules. 2022. PMID: 35458717 Free PMC article. Review.
-
[Efficacy of psychedelics in psychiatry, a systematic review of the literature].Encephale. 2021 Aug;47(4):376-387. doi: 10.1016/j.encep.2020.12.002. Epub 2021 Apr 20. Encephale. 2021. PMID: 33888297 French.
Cited by
-
An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers.Neurosci Appl. 2024 Dec 2;4:104092. doi: 10.1016/j.nsa.2024.104092. eCollection 2025. Neurosci Appl. 2024. PMID: 40654586 Free PMC article.
-
Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.Brain Behav. 2025 Jul;15(7):e70660. doi: 10.1002/brb3.70660. Brain Behav. 2025. PMID: 40619953 Free PMC article.
-
Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic.Front Psychiatry. 2023 Jun 15;14:1184681. doi: 10.3389/fpsyt.2023.1184681. eCollection 2023. Front Psychiatry. 2023. PMID: 37398594 Free PMC article.
-
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.Front Psychiatry. 2024 Feb 22;15:1349565. doi: 10.3389/fpsyt.2024.1349565. eCollection 2024. Front Psychiatry. 2024. PMID: 38455520 Free PMC article.
-
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.J Psychopharmacol. 2024 Oct;38(10):873-886. doi: 10.1177/02698811241278873. Epub 2024 Sep 20. J Psychopharmacol. 2024. PMID: 39302087 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources